Copyright
©2010 Baishideng.
World J Gastroenterol. Jan 14, 2010; 16(2): 225-231
Published online Jan 14, 2010. doi: 10.3748/wjg.v16.i2.225
Published online Jan 14, 2010. doi: 10.3748/wjg.v16.i2.225
Table 1 Characteristics of 366 ESRF patients (mean ± SD)
ESRF patients (n = 366) | |
Sex (M/F) | 243/123 |
Age (mean/range, yr) | 60.5/17-85 |
Haemodialysis duration (mo)1 | 49.2 ± 48.2 |
Dialysis type (haemodialysis/peritoneal dialysis) | 352/14 |
Known history of viral hepatitis (yes/no)2 | 51/315 |
History of transfusions (yes/no) | 129/247 |
Number of blood units | 6.8 ± 4.7 |
Duration of erythropoietin treatment (mo) | 46.2 ± 35.8 |
Table 2 Prevalence of HBV, HCV, and HEV serological markers, as well as HBV-DNA, in individual haemodialysis units n (%)
Unit 1 (n = 60) | Unit 2 (n = 70) | Unit 3 (n = 119) | Unit 4 (n = 56) | Unit 5 (n = 61) | Total (n = 366) | |
HBsAg | 9 (15) | 2 (2.9) | 3 (2.5) | 2 (3.6) | 4 (6.6) | 20 (5.5) |
Anti-HBs | 41 (68.3) | 39 (55.7) | 87 (73.1) | 38 (67.9) | 40 (65.6) | 245 (66.9) |
Anti-HBc | 32 (53.3) | 40 (57.1) | 39 (32.8) | 35 (62.5) | 29 (47.5) | 175 (47.8) |
HBeAg | 0 | 0 | 1 (0.8) | 1 (1.8) | 0 | 2 (0.5) |
Anti-HBe | 13 (21.7) | 14 (20) | 15 (12.6) | 17 (30.4) | 14 (23) | 73 (19.9) |
HBV-DNA | 6 (10) | 1 (1.4) | 3 (2.5) | 2 (3.6) | 3 (4.9) | 15 (4.1) |
Anti-HCV | 7 (11.7) | 27 (38.6) | 27 (22.7) | 20 (35.7) | 7 (11.5) | 88 (24) |
Anti-HEV | 3 (5) | 1 (1.4) | 4 (3.4) | 1 (1.8) | 6 (9.8) | 15 (4.1) |
Table 3 Epidemiological, biochemical and serological markers of HBV, HCV and HEV in 366 patients with ESRF according to HBV-DNA positivity (mean ± SD)
HBV-DNA | P value | ||
Positive (n = 15) | Negative (n = 351) | ||
Sex (M/F) | 12/3 | 231/120 | NS |
Age (yr) | 66 ± 13 | 60 ± 13 | NS |
Dialysis type (haemodialysis/peritoneal dialysis) | 15/0 | 337/14 | NS |
History of hepatitis (yes/no) | 0/15 | 51/300 | NS |
History of transfusions (yes/no) | 4/11 | 125/226 | NS |
Number of blood units | 3.5 ± 1.9 | 4.9 ± 5.2 | NS |
Duration of erythropoietin treatment (mo) | 30 ± 27 | 46 ± 36 | NS |
AST (UNL 40 U/L) | 17 ± 8 | 22 ± 19 | NS |
ALT (UNL 40 U/L) | 18 ± 11 | 26 ± 20 | NS |
HBsAg (pos/neg) | 12/3 | 8/343 | < 0.001 |
Anti-HBc (pos/neg) | 13/2 | 162/189 | 0.003 |
Anti-HBs (pos/neg) | 2/13 | 243/108 | < 0.001 |
HBeAg (pos/neg) | 1/14 | 1/350 | NS |
Anti-HBe (pos/neg) | 11/4 | 62/289 | < 0.001 |
Anti-HCV (pos/neg) | 0/15 | 88/263 | 0.03 |
Anti-HEV (pos/neg) | 1/14 | 14/337 | NS |
Table 4 HBV, HCV, and HEV serology in 15 HBV-DNA positive patients n (%)
HBsAg+ | 12 (80) |
HBsAg+, anti-HBc+, anti-HBe+ | 10 (66.7) |
HBsAg+, anti-HBc+, HBeAg+ | 1 (6.7) |
HBsAg+, anti-HBc+, anti-HBe+, anti-HBs+ | 1 (6.7) |
Anti-HCV+ | 0 (0) |
Anti-HEV+ | 0 (0) |
HBsAg- | 3 (20) |
HBsAg-, anti-HBc+, anti-HBs+ | 1 (6.7) |
HBsAg-, anti-HBc-, anti-HBs- | 2 (13.3) |
Anti-HCV+ | 0 (0) |
Anti-HEV+ | 0 (0) |
- Citation: Mina P, Georgiadou SP, Rizos C, Dalekos GN, Rigopoulou EI. Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. World J Gastroenterol 2010; 16(2): 225-231
- URL: https://www.wjgnet.com/1007-9327/full/v16/i2/225.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i2.225